We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Medlab Middle East to Return as Standalone Event in 2023

By LabMedica International staff writers
Posted on 11 Jan 2022
Illustration
Illustration

Informa Markets (London, UK), organizers of Medlab Middle East, have announced that the MENA region’s leading exhibition for the laboratory industry will return to a standalone event in 2023.

This announcement follows unprecedented demand from exhibitors and visitors for the 2022 edition of the show, which takes place at the Dubai World Trade Centre from 24-27 January 2022. As a result of the pandemic, Medlab Middle East and Arab Health co-located in 2021 to provide a platform for both the laboratory and general healthcare industries to come together, reconnect and do business face-to-face in a safe and secure environment. However, following high-level demand from leading laboratory companies to showcase their offering in a dedicated space, and from attendees keen to capitalize on the latest laboratory releases, the event will now revert to a standalone format, with dates confirmed for 7-9 February 2023.

The 2022 edition of Medlab Middle East is expected to welcome more than 400 exhibitors, a 100% increase from 2021. Key players participating in this edition include Roche, Siemens, Beckman Coulter, Abbott, Biomerieux and Mindray. In addition to the growth in exhibitors, which is expected to increase to over 500 in 2023, country pavilions have risen from nine in 2021 to 10 in 2022, with that figure expected to increase to 14 in 2023.

Fueling the surge in exhibitors is the anticipated growth in the global laboratory industry. According to the Global Clinical Laboratory Market – Analysis by test, end-user, by region, by country (2021 edition), the global laboratory market is expected to grow by a Compound Annual Growth Rate (CAGR) of 6% between 2021 and 2026, which puts the predicted value of the global laboratory market at US$ 33.07 billion by 2026. The report attributed the growth rate to the increasing number of lifestyle-related ailments and chronic illnesses, and spurts of infectious diseases in different parts of the world. The introduction of accurate and technologically advanced products, such as companion diagnostics, biochips, and microarrays, has bolstered the demand for early disease detection. Moreover, rapid technological advancements to enhance productivity and reduce costs are anticipated to boost the market further. These solutions offer clinicians maximum efficiency and minimum risk of errors, which has driven the uptake of services in the market.

“Advances in the medical laboratory have been pivotal in the defense against the continued threat that COVID-19 poses to industries around the world,” said Tom Coleman, Exhibition Director of Medlab Middle East. “Due to the speed at which the laboratory industry has responded to these threats by developing solutions, products and technology to counter the impact of the pandemic, we have seen a surge in companies wanting to showcase their latest innovations and from buyers eager to capitalize on these advances.”

“As a result of this demand, following the 2022 edition of the show, which will be held from 24 -27 January, Medlab Middle East will return as a standalone event in 2023 with a total of six halls, showcasing the latest innovations and new technologies being utilized in the laboratory industry,” added Coleman.

Related Links:
Informa Markets 

Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Human Estradiol Assay
Human Estradiol CLIA Kit
Gold Member
Collection and Transport System
PurSafe Plus®

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more